In its recent judgment, the Bombay High Court dismissed Bayer's appeal against the grant of a compulsory license (CL) to Natco, a generic manufacturer, for its Indian patent on an anti-cancer drug called Nexavar. This order of the Bombay High Court is round three in the litigation between Bayer & Natco. The first round was before the Controller General (CG) of Patents and the second round was before the Intellectual Property Appellate Board (IPAB).
